Skip to Main Content

One week after the New York City drug developer Applied Therapeutics announced it was working with regulators and law enforcement to identify and prosecute the anonymous author of a “fraudulent short report,” the company — much more quietly — amended its investor presentation in a way that bolsters accusations made by the author.

According to a Wall Street analyst who spoke with Applied Therapeutics, the addition of new data and clarifying language about a clinical trial to its corporate slide deck on July 9 was done to help investors better understand its work on an experimental drug for a rare metabolic disease.


But the changes to its slide deck were made to information and data that, in their prior form, were red-flagged as inconsistent, sloppy, and misleading by the author of the negative report — raising questions about the company’s true intent.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!